


RSC Chemical Biology

rsc.li/rsc-chembio



ISSN 2633-0679

REVIEW ARTICLE

Julio A. Camarero *et al.*
Resistance is futile: targeting multidrug-resistant bacteria
with *de novo* Cys-rich cyclic polypeptides

REVIEW



Cite this: *RSC Chem. Biol.*, 2023, 4, 722

Received 8th February 2023,
Accepted 27th July 2023

DOI: 10.1039/d3cb00015j

rsc.li/rsc-chembio

Resistance is futile: targeting multidrug-resistant bacteria with *de novo* Cys-rich cyclic polypeptides

Alvaro Mourenza,^{†a} Rajasekaran Ganesan^{†a} and Julio A. Camarero ^{*ab}

The search for novel antimicrobial agents to combat microbial pathogens is intensifying in response to rapid drug resistance development to current antibiotic therapeutics. The use of disulfide-rich head-to-tail cyclized polypeptides as molecular frameworks for designing a new type of peptide antibiotics is gaining increasing attention among the scientific community and the pharmaceutical industry. The use of macrocyclic peptides, further constrained by the presence of several disulfide bonds, makes these peptide frameworks remarkably more stable to thermal, biological, and chemical degradation showing better activities when compared to their linear analogs. Many of these novel peptide scaffolds have been shown to have a high tolerance to sequence variability in those residues not involved in disulfide bonds, able to cross biological membranes, and efficiently target complex biomolecular interactions. Hence, these unique properties make the use of these scaffolds ideal for many biotechnological applications, including the design of novel peptide antibiotics. This article provides an overview of the new developments in the use of several disulfide-rich cyclic polypeptides, including cyclotides, θ -defensins, and sunflower trypsin inhibitor peptides, among others, in the development of novel antimicrobial peptides against multidrug-resistant bacteria.

Introduction

According to the Centers for Disease Control and Prevention, the six ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter species*) bacterial species cause around two-thirds of healthcare-associated infections (e.g., pneumonia, septicemia), leading to close to 99 000 deaths annually in the United States.¹ A trait of these emerging difficult-to-treat clinical superbugs is their ability to “escape” the action of multiple traditional antibiotics, in part due to biofilm formation as well as mechanisms of drug resistance. It is estimated that globally, at least 1.2 million people died in 2019 because of bacterial infections caused by multidrug-resistant (MDR) bacterial strains.² It is expected that the rapid spread of MDR bacterial strains may cause about 10 million deaths per year globally by 2050.² These terrifying facts seriously highlight the urgent need to develop novel antibiotic therapeutic agents.

Several approaches have been proposed for the development of novel antimicrobial therapeutics. For example, the use of

antibody protein pseudo capsids, probiotics, metal chelation, CRISPR-Cas9, bioengineered toxins, bacteriocins, vaccines and antibodies are also currently being explored to overcome antibiotic resistance (see ref. 3 and references cited there).

Among the different approaches this review will focus on the use of highly constrained peptides, specifically on highly constrained disulfide-rich backbone-cyclized antimicrobial peptides. Antimicrobial peptides are essential host defense molecules found in a wide variety of species and have been proposed as promising antibacterial therapeutic candidates.⁴ To date, several hundreds of antimicrobial peptides have been identified in a variety of life forms ranging from bacteria, fungi, plants, amphibians, and mammals, including humans.^{5,6} In mammals, cathelicidins, protegrins, and defensins are the three major types of host defense peptides.^{7,8}

However, the utility of these peptides as antimicrobial therapeutic agents has been typically hampered by their generally poor stability and limited bioavailability.⁹ To overcome these limitations, the use of highly constrained peptides has recently received special attention, mostly through backbone cyclization, incorporation of non-natural amino acids, and Cys-based disulfide bridges for the design of novel peptide-based antimicrobial agents with better stability.^{10–13}


In this review, we will present recent developments in the use of Cys-rich cyclic polypeptides for designing novel peptide antibiotics. Cyclic Cys-rich peptides are widely distributed natural product polypeptides among different species, including animals

^a Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy, Los Angeles, CA90033, USA. E-mail: jcamarero@usc.edu; Tel: +1-(323) 442-1417

^b Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA90033, USA

[†] Equal contribution.





Scheme 1 Schematic representation of the structural complexity of naturally occurring disulfide-rich cyclic peptides that are commonly used as molecular scaffolds for the development of novel antibacterial therapeutic leads. Techniques used to improve or introduce antimicrobial activities include the use of SAR introducing charged/hydrophobic or non-natural amino acids, backbone cyclization, molecular grafting, and evolution techniques. As indicated in the test, some of these engineered constructs have shown to exhibit high activity against multi-drug resistant (MDR) pathogenic bacteria. Molecular structures shown on the scheme include θ -defensins (RTD-1, pdb: 1HVZ),¹⁵⁶ BBI peptides (sunflower trypsin inhibitor 1, SFTI-1, pdb: 1JBL),¹⁵⁷ α -defensins (cryptidin 4, pdb: 2GW9),¹⁵⁸ cyclotides (cycloviolacin O2, pdb: 1NBJ),¹⁵⁹ and β -hairpin antimicrobial peptides gomesin (pdb: 1KFP)¹³⁷ and porcine PG-1 (pdb: 1PG1).⁶⁷

and plants (Scheme 1). They have attractive features, including thermal, chemical, and biological stability against proteases. Peptides that will be discussed in this review include the use of cyclotides, mammalian defensins, and sunflower protease inhibitor 1, among others, as molecular frameworks to produce novel peptide-based antimicrobial agents.

Defensins

Defensins are Cys-rich peptides containing three disulfide bridges that belong to the β -sheet class of antimicrobial peptides in vertebrates.¹⁴ Defensins are small (29 to 42 residues long), mostly cationic and amphipathic peptides showing broad-spectrum and direct and indirect antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and viruses.¹⁵ Defensins can be divided into three subfamilies: α -, β -, and θ -defensins, depending on the position of the Cys residues forming the corresponding disulfide bridges (Fig. 1 and Table 1).¹⁴ While α - and β -defensins are linear polypeptides

that are widely distributed in vertebrate species, θ -defensins are backbone cyclized or circular cyclic polypeptides found only in certain non-human primates (Fig. 1).^{16,17}

α - and β -Defensins

Defensins were initially discovered in rabbit lung macrophages being later also reported in other vertebrate species.¹⁴ Defensin-like peptides have also been isolated from plants, where they were initially classified as γ -thionins¹⁰ and later classified as defensins based on sequence homology, structure, and functional similarity with animal defensins.¹⁸ Despite the fact that plant defensins have a quite similar amphiphilic β -sheet structure to that of animal defensins, their evolutionary relationship is unclear (see ref. 10 for an extensive review on plant defensins).

Defensins can kill bacteria or inhibit their growth through a multiplicity of antimicrobial mechanisms such as direct membrane disruption^{10,19,20} and inhibition of bacterial cell wall synthesis.^{21–23} Although defensins are classically known for their antimicrobial activities, they also possess many other




Fig. 1 Families and structures of different Cys-rich cyclic peptides used as molecular frameworks for the design of novel antimicrobial peptides as described in the manuscript. These include α -defensins: Crp4 (PDB: 2GW9),¹⁵⁸ β -defensins: hBD1 (PDB: 1IJV),¹⁶⁰ hBD2 (PDB: 1FD3),¹⁶¹ hBD3 (PDB: 1KJ6)¹⁶² and RTD1 (PDB: 1HVZ),¹⁶³ cathelicidins: PG-1 (PDB:1PG1)⁶⁷ and LL-37 (pdb: 7PDC),¹⁶⁴ Cys-rich backbone cyclized peptides: kalata B1 (pdb: 1NB1),⁹⁹ cycloviolacin O2 (pdb: 1DF6)¹⁵⁹ and SFTI-I (pdb: 4TTK),¹³⁷ and β -hairpin peptides: gomesin (pdb: 1KFP)¹³⁷ and thanatin (pdb: 5XO4). Their primary structures and antimicrobial properties are summarized in Table 1.

Table 1 Summary of the bioactive peptides' primary structures and antimicrobial activities showed in Fig. 1. NA stands for non-available

Group	Peptide name	Sequence and disulfide structure	MIC (μM)	Ref.
α -Defensin	CRP4	GLICYCRKGHCCKRGERV ¹ RGTCGIRFLYCC ² PRR	< 5	38 and 39
β -Defensins	hBD-1	DHYN ¹ CVSSGGQCLYSAC ² PIFTKI ³ QGT ⁴ CYR ⁵ GKAK ⁶ CCK	N.A. oxidized	49
	hBD-2	GIGDPVTCLKSGAICH ¹ PVFC ² PRRYK ³ QIGTCGLPGTK ⁴ CCK ⁵ KKP	2.3–23	50
	hBD-3	GIINTLQKY ¹ YCRV ² RRGRC ³ AVLSCL ⁴ PK ⁵ EEQIGK ⁶ CSTRGRK ⁷ C ⁸ RR ⁹ KK	0.7–1.2	51
θ -Defensin	RTD-1	GFCR ¹ CLCRRGV ² CR ³ CI ⁴ TR	0.5–5	61 and 62
Cathelicidins	PG-1	RGGRLCY ¹ RRR ² FC ³ VC ⁴ VGR	0.03–0.4	72 and 76
	LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN ¹ LVPR ² TES	1–10	88
Cyclotides	Kalata B1	CGETCVGGTCNT ¹ PGCTCSWPV ² CTR ³ NGL ⁴ PV	0.29–14	122
	MCo-PG2	CGSGSGGRLCY ¹ RRR ² FC ³ VC ⁴ VRRGGV ⁵ CPKILQ ⁶ RCRR ⁷ SD ⁸ CPGAC ⁹ ICR ¹⁰ GNGY	0.8–12.5	77
SFTI-I derived	RV3	RVRVRV ¹ VRV ² RV ³ RV ⁴ CTK ⁵ SIP ⁶ PI ⁷ CF	0.6–4	134 and 135
β -Hairpin	Gomesin	Q ¹ CRRLCY ² KQ ³ RC ⁴ VTY ⁵ CR ⁶ GR ⁷ X	0.2–6	136
	Thanatin	GSKKPV ¹ PII ² CNR ³ RTG ⁴ K ⁵ C ⁶ Q ⁷ RM	0.5–2	142 and 143

defense-involved activities, including wound healing,^{24,25} immune modulation,^{26–29} neutralization of endotoxins,^{30,31} and anti-cancer activities.³²

Mammalian α -defensins are, in general, less cationic and more hydrophobic than β -defensins (hBDs) (Table 1), and they use different mechanisms to kill bacteria.¹⁹ For example, while

hBD-1 and hBD-2 show better activity against Gram-negative bacteria,³³ hBD-3 displays potent bactericidal activity against both Gram-positive and Gram-negative bacteria.^{34,35}

The antibacterial activity of α - and β -defensins is highly dependent on the ionic strength of the media, and salt-dependent inactivation of defensins in patients with cystic fibrosis has been proposed as the potential cause of chronic pulmonary infections in these patients.³⁶

The antimicrobial activity of the naturally cyclic θ -defensins (Fig. 1 and Table 1), in contrast, has been shown to be less sensitive to salt concentration than α - and β -defensins.³⁷ This difference has been attributed to the circular structure of θ -defensins since the acyclic forms are more salt sensitive.³⁷ In agreement with this hypothesis, the replacement of the characteristic Cys–Cys disulfide bridge end-to-end, Cys^{3,31} (Cys I:Cys VI) in the rabbit α -defensin neutrophil peptide 1 (NP-1) by a backbone-cyclization, provided biologically active defensin analogs that were less sensitive to salt.³⁸ No studies, however, were provided in this work on the stability of the resulting engineered circular α -defensins lacking the characteristic C- to N-termini Cys–Cys disulfide bridge. In another independent study, the backbone-cyclization of the native α -defensin cryptidin-4 (Crp4) from murine Paneth cells demonstrated that the backbone-cyclized version of Crp4 was able to adopt a natively-folded α -defensin structure displaying equivalent or better microbicidal activities against several Gram-positive and Gram-negative bacteria when compared to the native linear Crp4.³⁹ Both forms of Crp4, linear and circular, showed no detectable hemolytic activity against human red blood cells. In addition, the circular version of Crp4

displayed significantly higher stability against proteolytical degradation when incubated with human serum.³⁹ The presence of the disulfide array in Crp4 has previously been shown to be a necessary component in resistance to proteolytic degradation but does not affect antimicrobial activity.⁴⁰ These properties make cyclized Crp4 α -defensins promising scaffolds for drug development of novel antibiotics, although further studies may be required to evaluate their metabolic stability and bioavailability.

The hydrophobic and highly cationic nature of defensins favors the accumulation of these peptides on the mostly negatively charged bacterial membranes in both Gram-positive and Gram-negative bacteria independently of their actual target of action.⁴¹ For many years, it was believed that the mechanism of action of defensins was the permeabilization of the bacterial membranes. Different models have been proposed for the membrane permeabilization of antimicrobial peptides (Fig. 2). These include: (i) the barrel-stave pore model, where the peptide molecules can use their amphipathic nature to form dimers or multimers that cross the membrane forming barrel-like channels,⁴² (ii) the toroidal pore model where the defensin creates a monolayer connecting the outer and the inner lipid layers in the pore;⁴³ (iii) the carpet model, where antimicrobial peptides produce a carpet-like structure that covers the outer surface of the membrane and disrupts it in a detergent-like mechanism of action;⁴⁴ (iv) other less frequent models involve the sinking-raft and the molecular electroporation models, where the peptide molecules can either bind or sink into the bacterial membrane or just disrupt the electrostatic potential across the membrane to generate pores.⁴⁵




Fig. 2 Different types of models proposed for the molecular mechanism of action of antimicrobial peptides.^{41,165}

More recent studies have suggested that some defensins can exert their antibacterial activity using alternative modes of action (Fig. 2).⁴¹ For example, human defensins can also interact with additional bacterial targets to kill bacteria. α -Defensin HNP1 has been shown to interact mostly with the bacterial membrane in *Escherichia coli* but instead employs a different bactericidal mechanism on *Staphylococcus aureus* by interacting and inhibiting the cell-wall precursor lipid II.²³ The bactericidal activity of α -defensins HNP2 and HNP3 also involve lysing the bacterial membrane, although HNP2 has also been reported to produce aggregation and fusion of vesicles as alternative mechanisms of action for its bactericidal activity.⁴⁶ Interestingly, HNP4, the less abundant of the α -defensins found in the azurophilic granules of neutrophils, is about 100 times more active against *E. coli* than its homologs HNP1-3 and also targets the bacterial membrane.⁴⁷ Other α -defensins like HD5 and HD6 also have been shown to permeabilize the bacterial cell membrane as the main mechanism for their bactericidal activity.⁴⁸ HD5 has, in addition, the ability to bind strongly to DNA, suggesting that this interaction may be key in dysregulating essential processes associated with DNA replication, transcription, or translation of genes involved in bacterial survival.⁴⁹

The proposed role for β -defensins like hBD1 is acting like a protective barrier for epithelial cells, therefore, preventing infection by commensal bacteria.⁵⁰ Although the antimicrobial activity of hBD1 has been found to be lower than other defensins, after the complete reduction of its three disulfide bridges, its antimicrobial properties become more potent but also more labile to proteolytic degradation.⁵⁰ In human skin, hBD1 is found colocalized with the redox protein thioredoxin, which supports the hypothesis that thioredoxin may act as an *in situ* physiological mediator catalyzing the reduction of the less active folded hBD1 into the most active, fully reduced form of hBD1 in human epithelia.⁵⁰ Other β -defensins, like hBD2-4, also employ the common mechanism of action by binding to the negatively charged bacterial membrane and causing membrane permeabilization and cellular death.^{51,52} In addition, hBD3 has also been shown to bind and inhibit lipid II, perturbing the bacterial cell wall biosynthesis.⁵²

θ -Defensins

In contrast with α - and β -defensins, θ -defensins are naturally backbone cyclized antimicrobial peptides which are formed by the head-to-tail covalent assembly of two nonapeptides derived from α -defensin related precursors^{37,53} (see ref. 17 for an extended review on the chemistry and biology of θ -defensins). As mentioned earlier, θ -defensins are, to date, the only known backbone-cyclized polypeptides expressed in animals³⁷ and show antimicrobial activities in the 0.5–5 μM range. The antimicrobial activity of θ -defensins is less sensitive to physiological salt content when compared to α - and β -defensins, which can be attributed to their backbone circular topology as the linear analog of the Rhesus defensin 1 (RTD-1) is about three times less active than the cyclic RTD-1.³⁷ Interestingly, it has been reported that the disulfides of θ -defensins are not essential for antimicrobial activity.⁵⁴ θ -Defensins have also been shown to bind and neutralize bacterial toxins such as anthrax lethal factor.^{55–57}

The recent development of efficient approaches for the chemical and recombinant production of θ -defensins^{53,56–59} has allowed the rapid and efficient production of many θ -defensin analogs to study their chemical and biological properties.¹⁷ The recent use of a ‘tea-bag’ approach⁶⁰ in combination with a one-pot cyclization method involving native chemical ligation and oxidative folding allowed the development of more potent analogs of θ -defensin RTD-1 that can inhibit anthrax lethal factor (LF) as well as the TNF- α converting enzyme (TACE) with K_i values ≈ 40 nM and ≈ 157 nM, respectively.⁵⁶

Natively folded and bioactive θ -defensin RTD-1 has also been produced in high yield (0.7 mg of RTD-1 per gram of wet cells) inside *E. coli* cells by making use of intracellular protein trans-splicing in combination with a highly efficient split-intein.⁵⁷ This approach was employed to produce a genetically-encoded RTD-1-based peptide library in *E. coli* cells encoding $\approx 2 \times 10^7$ different RTD-1-based sequences.⁵⁷ This result is intriguing as θ -defensins possess antimicrobial activities against several microbial pathogens, including *P. aeruginosa*, *S. aureus* and *E. coli*, pathogenic yeast *Candida albicans*, and HIV.^{61,62} θ -Defensins also display potent anti-inflammatory properties *in vitro* and *in vivo* mediated by the suppression of numerous pro-inflammatory cytokines and blockade of TNF- α release by inhibition of TACE.⁶³ A potent TACE inhibitor was recently developed using the Rhesus θ -defensin as a molecular scaffold.⁵⁶

Cathelicidins

Cathelicidins are antimicrobial peptide precursors widely distributed in mammalian and some fish granulocytes and certain epithelia. Their name indicates the presence of a cathelin domain, a well-conserved structural element of about 100 amino acids, that is followed by a C-terminal antimicrobial peptide domain. The C-terminal antimicrobial domain can adopt α -helical, β -sheet, or other structures once released by proteolytic cleavage. Cathelicidins are considered part of the innate immune system in many vertebrates and show in general a broad-spectrum antimicrobial activity against bacteria, some enveloped viruses, and fungi. In addition to their antimicrobial activity, cathelicidins are also able to activate host defense responses (see ref. 64 for a detailed review of cathelicidins).

Protegrins

Mature protegrins are Arg and Cys-rich cationic polypeptides 16 to 18 residues long with an amidated C-terminus.⁶⁵ Protegrins adopt a β -hairpin structure stabilized by two disulfide bridges (Fig. 1 and Table 1). Protegrins were first discovered in porcine leukocytes,⁶⁵ and their structure resembles that of the θ -defensins⁵³ and tachyplesin/polyphemusin peptides found in the hemocytes of horseshoe crabs.⁶⁶

Five different porcine protegrins (PGs) have been isolated and characterized, PG-1 through PG-5.⁶⁵ Protegrins show broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, including multi-drug resistant bacterial strains.⁶⁷ They can bind important components of microbial membranes, including lipopolysaccharides (LPS),

lipid A and lipoteichoic acid (LTA),⁶⁸ which help them to insert into the bacterial membrane and permeabilize it.⁶⁹ Protegrins have also shown antiviral activity against HIV-1⁷⁰ and HSV-2,⁷¹ enveloped virus responsible for AIDS and genital herpes.

In contrast with defensins, protegrins have a broader antimicrobial pH range, being effective against acid-tolerant microorganisms even at pH 4.5.⁶⁸ Another interesting feature of protegrins is that their antimicrobial activity is not affected by physiological NaCl concentration, also remaining largely unaffected by the presence of divalent cations.⁷² The salt tolerance observed in protegrins is imparted by the disulfide bridges, which stabilize the β -hairpin even in the presence of high salt content.^{68,72} For example, a disulfide-free protegrin analog of PG-1, obtained by replacing each Cys residue with Ala, displayed similar antimicrobial activity to that of the native disulfide-containing protegrin but was practically inactive in media containing 100 mM NaCl.⁷²

The presence of serum proteins also has a negligible effect on the antimicrobial activity of protegrins, and in some cases, it has been described to have a positive effect enhancing their antimicrobial activity, likely through the additive effects of complement or other serum constituents.⁶⁸ This is completely the opposite effect that human serum has on α -defensins, where several serum components (*e.g.*, α 2-macroglobulin and serpins) avidly bind human α -defensins, significantly reducing their antimicrobial activity.⁷³

On the other hand, native protegrins also display high cytotoxicity and hemolytic properties against eukaryotic and red blood cells.⁷⁴ Cytotoxicity to eukaryotic cells has also been described for other β -sheet antimicrobial peptides like tachyplesin and polyphemusin peptides.⁷⁵

Extensive structure–activity studies have been carried out in porcine protegrins to define the importance of sequence length, residue chirality, C-terminal amidation state, and disulfide-bridge structure required for the antimicrobial and cytotoxic activity of protegrins in order to improve their biological activity and reduce cytotoxicity.⁷⁶ Several studies have shown that the introduction of structural alterations on protegrins can greatly reduce their cytotoxic properties while keeping intact their broad-spectrum antibacterial activity.^{72,76,77}

Backbone cyclization and introduction of an extra disulfide in the β -sheet region to produce a cyclic tri-cystine analog of protegrin PG-1 has been shown to reduce about 10 times the hemolytic activity of PG-1 while improving 6 to 30 times the membranolytic selectivity against several pathogenic microorganisms.⁷² Introduction of the V14T mutation on PG-1 also significantly reduced the cytotoxicity against mammalian cells while keeping similar antibacterial activity to that of the parent PG-1 peptide.⁶⁸

The porcine PG-1 was used as starting point to generate the analog IB-367, also known as iseganan.⁷⁸ IB-367 has shown promising results in the prevention of chemotherapy- and radiation-induced oral mucositis, and the drug has been evaluated in phase III clinical trials for this application.^{79,80}

Murepavadin, also known as POL7080, is a recently developed synthetic cyclic β -hairpin peptidomimetic based on

protegrin PG-1.^{81,82} This antibacterial peptide was designed by using a D-Pro-L-Pro template to mimic and stabilize the β -hairpin conformation of PG-1 generating a diverse peptide library that was then screened for antibacterial activity.⁸³ Murepavadin is a highly active *Pseudomonas* spp-specific peptide antibiotic that targets the outer membrane protein transporter LptD of *P. aeruginosa*.⁸² This is the first example of a peptide antibiotic with a novel nonlytic mechanism of action. This peptide has shown very potent bactericidal antimicrobial activity against *P. aeruginosa in vitro*, including over 1000 multidrug-resistant (MDR) clinical isolates of *P. aeruginosa*.^{84–86}

These results, together with the good safety profile observed in a phase 1 study,⁸⁷ and combined with results from ongoing clinical studies, are highly encouraging to continue further clinical development of murepavadin for treating serious *P. aeruginosa* infections.⁸⁴

More recently, a topologically modified version of protegrin PG-1 was also used to generate novel antibacterial cyclotides with effective broad-spectrum antibacterial activity against several ESKAPE bacterial strains and a panel of MDR clinical isolates of *P. aeruginosa* and *S. aureus*.⁷⁷ The most active antibacterial cyclotide showed similar activity to that of PG-1 while displaying little hemolytic activity and being extremely stable in serum.⁷⁷ This novel cyclotide was also able to provide *in vivo* protection in a murine model of *P. aeruginosa* peritonitis.⁷⁷

LL-37

Despite the great abundance of β -defensin-encoding genes in the human body, LL-37 is the only cathelicidin identified so far in humans.⁶⁴ LL-37 is expressed as the protein precursor hCAP-18 that is stored in cytoplasmic granules and lamellar bodies.⁶⁴ The C-terminal segment of hCAP18 is then proteolytically cleaved by proteinase 3, providing the fully active 37-residue long LL-37 peptide.⁶⁴ Expression and secretion of LL-37 is mostly carried out by epithelial cells, although immune cells are also known to express and secrete peptide LL-37.⁶⁴ LL-37 shows good antimicrobial activity against Gram-negative and Gram-positive bacteria with MIC values ranging from 1–10 μ M depending on the method used to calculate it and the bacteria strain.⁸⁸ The antibacterial activity of LL-37 is through direct interaction and disruption of the bacterial membrane, although it also shows strong immunomodulatory properties.⁶⁴

Mature LL-37 is a linear peptide with a high α -helical content in physiological buffers. The α -helical content has been estimated to be around 35% at pH 7.4.⁸⁹ The helicity of the LL-37 increases upon binding to the bacterial membrane, which is a common feature observed in lipid-binding peptides.⁸⁹ Synthetic LL-37 peptide analogs have been evaluated in clinical trials for treating venous leg ulcers.⁹⁰

Despite the interesting bioactivities of LL-37, its clinical potential has been mainly hampered by its proteolytic instability and cytotoxicity.⁹¹ To overcome these issues, different approaches have been employed for the stabilization of LL-37.

The N-terminal fragment of LL-37, peptide LL-12, completely lacks any antibacterial activity.⁹² The C-terminal region of LL-37, in particular the segment corresponding to LL-37 (18–29), also




Fig. 3 Design of peptide CD4-PP, a cyclo-homodimer based on an improved KR12 peptide (LL37 218–29 fragment) containing activating mutations Q5A and D9K (shown in green). The optimized KR12 Q5A, D9K was used to produce a backbone cyclized anti-parallel homodimer. The flexible linker G/CPGG (shown in blue) was used to join the identical α -helical segments.⁹⁶ The resulting cyclic peptide CD4-PP displayed 16-fold higher antibacterial activity compared to KR-12 against *P. aeruginosa* and *S. aureus*, and 8-fold increased fungicidal activity against *C. albicans*.⁹⁶

known as peptide KR12, retains most of the antimicrobial activity of LL-37 while also showing reduced cytotoxicity.^{93,94} The activity of KR12 can be further improved by introducing specific mutations, Q5A and D9K, in the peptide sequence.⁹⁵ KR12-derived linear peptides, however, are highly susceptible to proteolytic degradation. A recent report used a backbone cyclized homodimer of the improved KR12 Q5A, D9K analog sequence to improve its stability to proteolytic degradation (Fig. 3).⁹⁶ The most active peptide, CD4-PP, displayed 16-fold higher antibacterial activity compared to KR-12 against *P. aeruginosa* and *S. aureus*, and 8-fold increased fungicidal activity against *C. albicans*.⁹⁶ Unfortunately, CD4-PP also displayed increased hemolytic and cytotoxic activity.⁹⁶ This interesting work on peptide KR-12 suggests that backbone cyclodimerization can be used as an effective strategy to improve both the potency and stability of linear antimicrobial peptides, although more studies may be required to decrease the hemolytic and cytotoxic activity of CD4-PP.

Cyclotides

Cyclotides are fascinating circular Cys-rich micro-proteins containing ≈ 30 residues and three disulfides that are found in plants.⁹⁷ Cyclotides display various biological properties such as protease inhibitory, antimicrobial, insecticidal, cytotoxic, anti-HIV, and hormone-like activities (see ref. 12, 13 and 98 for recent reviews of the properties and applications of cyclotides).

They share a unique head-to-tail cyclic cystine knot (CCK) scaffold of three disulfide bridges, with one disulfide penetrating through a macrocycle formed by the two other disulfides and interconnecting peptide backbones, forming what is called a cystine knot topology (Fig. 1 and 4).⁹⁹ The main features of cyclotides are remarkable stability due to the cystine knot, a small size making them readily accessible to chemical synthesis, and an excellent tolerance to sequence variations. Cyclotides have also been shown to be orally bioavailable,^{100,101} and capable of crossing cell membranes^{102,103} to efficiently target extracellular^{104–106} and intracellular molecular targets *in vivo*.¹⁰⁷ Cyclotides also display poor immunogenicity due to their highly constrained nature.^{108,109} All these properties make them an ideal scaffold for peptide drug design.^{13,98,110}

Naturally-occurring cyclotides from the Möbius and bracelet subfamilies display strong insecticidal activity and are thought to work mainly as host-defense agents.^{111–116} Other biological activities reported for cyclotides from these two subfamilies also include inhibiting the growth of parasitic worms.^{117–119}

Folded cyclotides from these two subfamilies display well-defined hydrophobic and hydrophilic patches on the molecular surface, conferring them an amphipathic character.¹²⁰ These amphipathic properties are also typically found in classical antimicrobial peptides. This molecular characteristic has been used to explain their antibacterial activity.¹²¹ For example, the Möbius cyclotide kalata B1 has been described to possess antimicrobial activity against Gram-positive and Gram-negative bacteria.¹²² Other cyclotides isolated from plants have also shown similar antimicrobial activities.^{123–125} The more potent naturally-occurring antimicrobial cyclotide tested so far is the bracelet cyclotide cycloviolacin O2.¹²⁶ This cyclotide also showed activity against *S. aureus* in a mouse infection model.¹²⁷ As with many other antimicrobial peptides, the *in vitro* antimicrobial activity of these types of cyclotides strongly depends on the buffer composition, showing promising antimicrobial activity only in low salt content buffers. This may suggest that the *in vivo* antimicrobial activity of cycloviolacin O2 could also be due to an indirect effect.

Cyclotides can also be used as molecular frameworks to introduce other biological activities. For example, a recent study reported the first design and synthesis of a novel cyclotide with broad-spectrum antimicrobial activity *in vitro* against different ESKAPE pathogens (*P. aeruginosa*, *S. aureus*, *K. pneumoniae*, and *E. coli*), including 20 MDR clinical isolates for the human pathogens *S. aureus* and *P. aeruginosa* (Fig. 4). The median minimal inhibitory concentration (MIC) 50% (MIC₅₀) and MIC 90% (MIC₉₀) values for several MDR clinical strains of *P. aeruginosa* were 1.5 μM and 3.1 μM , respectively; while for clinical isolates of MDR *S. aureus* the MIC₅₀ and MIC₉₀ values were 6.25 μM and 12.5 μM , respectively.⁷⁷ More importantly, the most active cyclotide, MCo-PG2, showed strong antimicrobial activity *in vivo* using a murine model of acute *P. aeruginosa* peritonitis.⁷⁷ Cyclotide MCo-PG2 was shown to improve the survival rate in a peritonitis mice model using the clinical isolate of *P. aeruginosa* (ATCC 27853) from 0%, for the untreated mice group, to 90% for the mice group treated with 25 mg kg⁻¹ of cyclotide.⁷⁷




Fig. 4 Design of antimicrobial cyclotide MCo-PG2 using molecular grafting. A topologically modified version of protegrin 1 (PG-1) was grafted into loop 6 of trypsin inhibitor cyclotide MCoTI-II. The resulting engineered cyclotide precursor was readily produced by solid-phase peptide synthesis. The crude linear thioester was then cyclized and oxidatively folded in a “one-pot reaction”.⁷⁷ The resulting cyclotide, MCo-PG2, displayed broad-spectrum antimicrobial activity *in vitro* against different ESKAPE pathogens (*P. aeruginosa*, *S. aureus*, *K. pneumoniae*, and *E. coli*), including 20 MDR clinical isolates for the human pathogens *S. aureus* and *P. aeruginosa*. Cyclotide MCo-PG2 also improved the survival rate in a peritonitis mice model using the clinical isolate of *P. aeruginosa* (ATCC 27853) from 0% for the untreated mice group to 90% for the mice group treated with 25 mg kg⁻¹ of cyclotide.⁷⁷

The results reported with cyclotide-MCo-PG2 are very encouraging, demonstrating for the first time the design of a novel cyclotide exhibiting potent antimicrobial activity under physiological-like conditions and showing also strong *in vivo* antibacterial efficacy in a murine *P. aeruginosa*-induced peritonitis animal model.⁷⁷

The trypsin inhibitor cyclotide MCoTI-II has also recently been used to graft potent antimicrobial peptide optP7 (H-KRRVRWIIW-NH₂)¹²⁸ to produce antimicrobial cyclotide [L6-Opt7]-Mco.¹²⁹ Some of the fractions obtained during the folding of this cyclotide exhibited promising antimicrobial activity against a panel of ESKAPE pathogens, with MIC values in the low μM range.¹²⁹ MIC values were, however, obtained under optimized buffer conditions, and the antimicrobial activity was shown to be strongly dependent on the ionic strength of the assay buffer.¹²⁹ Unfortunately, this is a feature commonly found in many antimicrobial peptides. The activity dependence on ionic strength of cyclotide [L6-Opt7]-Mco, however, could be attributed to the intrinsic properties of the grafted sequence, peptide optP7.¹²⁸ In contrast, the activity of cyclotide MCo-PG-2, based on cyclotide MCoTI-I and protegrin PG-1, was not affected by the buffer composition and exhibited full activity *in vivo* using a peritonitis animal model.⁷⁷

Sunflower trypsin inhibitor 1 (SFTI-1)

SFTI-1 is a 14 amino acid backbone-cyclized peptide containing a single disulfide bond that is naturally found in the seeds of the sunflower plant (*Helianthus annuus*).¹³⁰ SFTI-1 belongs to the Bowman-Birk inhibitor (BBI) family, whose members are

found in many plants and are potent serine protease inhibitors.¹³¹ Structural analysis of SFTI-1 shows a well-defined double β-hairpin loop linked by two short anti-parallel β-strands (Fig. 1).¹³² The backbone-cyclized SFTI-1 is the smallest and the most potent protease member of the family with a *K_i* against trypsin in the low nM range.¹³³

The relatively rigid backbone of SFTI-1 makes it extremely resistant to proteolytic degradation and a good molecular framework to introduce novel biological activities.¹³⁰ A recent report used the trypsin-binding loop (CTKSIPPIC) of SFTI-1 as a scaffold to design a novel type of peptide antibiotic. In this work, several peptides designed using an alternate arrangement of hydrophobic and cationic amino acids ((RX)_nW(RX)_m, where *n* = 2 or 3, and X represents a hydrophobic residue) were fused to the N-terminal of the oxidized trypsin-binding loop (CTKSIPPIC) of SFTI-1.¹³⁴ The most active peptide, RV3 (*n* = 3 and X = Val), displayed broad antimicrobial activity against Gram-positive and Gram-negative bacteria, with MIC values ranging from 1 to 4 μM, and showed antimicrobial efficacy in a mouse skin inflammation model established by *P. aeruginosa* infection.¹³⁴ Peptide RV3 was able to effectively kill the pathogen, promote wound healing, inhibit inflammatory cell infiltration, and inhibit mRNA and protein expression of TNF-α, IL-6, and IL-1β inflammatory factors.¹³⁴ This study concluded the mechanism of action of RV3 involved binding to lipopolysaccharides in the bacterial membrane, increasing the cell membrane permeability and finally leading to cell membrane rupture and death.¹³⁴

Another study recently reported the design of a hybrid antimicrobial peptide using the trypsin binding loop (loop 1) of SFTI-1 and the sequence corresponding to loop 2 of peptide HVBBI.¹³⁵ HVBBI is a β-hairpin BBI peptide found in the skin

secretions of the Chinese bamboo odorous frog.¹³⁵ The resulting hybrid peptide, HSEP-1, displayed only modest antimicrobial activities against *Micrococcus luteus* (MIC \approx 40 μ M). Further optimization of HSEP-1 by increasing the hydrophobicity of loop 2 and charge of the peptide yielded peptide HSEP-3. This peptide displayed a MIC value of 0.6 μ M against *M. luteus*, although antimicrobial activity against other bacterial pathogens was rather modest.¹³⁵ These designed peptides elicit their antibacterial action *via* both membrane destabilization and inhibition of intracellular trypsin, which are attributable to the two separate peptide segments, loop 1 (trypsin binding loop) and loop 2 (antimicrobial segment). The toxicity studies and food preservation assays in this work indicated good safety and efficacy profiles for its potential use as a food preservative, although more optimization may be required before its commercial application.¹³⁵

β -Hairpin-containing peptides of arthropod origin

Gomesin

Gomesin is an 18-residue long Cys-rich cationic antimicrobial peptide originally isolated from the hemocytes of the Brazilian tarantula *Acanthoscurria gomesiana* (see ref. 136 for a recent review on the structural and biological properties of gomesin) (Fig. 1 and Table 1). The peptide shows potent cytotoxic activity against clinical isolates of bacteria, including pathogenic Gram-positive and Gram-negative, fungi and yeast with MIC values ranging in all cases from 0.2 μ M to 6 μ M.¹³⁶

The solution structure of gomesin shows that the peptide adopts a β -hairpin-like structure, with two-stranded anti-parallel β -strands connected by a 4-residue non-canonical β -turn (Y7-K8-Q9-R10) (Fig. 1).¹³⁷ The β -strands are stabilized by two inter-strand disulfide bridges (C2-C15 and C6-C11) and six inter-strand backbone-backbone hydrogen bonds.¹³⁷

Numerous studies have been reported on the chemical modification of gomesin to increase its antibacterial activity while reducing its hemolytic properties.¹³⁸⁻¹⁴⁰ For example, a report showed that backbone cyclization produced a circular analog of gomesin that was more resistant to serum proteases and able to retain the potent anticancer and antimicrobial activities of native gomesin.¹³⁹ Cyclization of gomesin usually produces a 2- to 3-fold increase in its antimicrobial activity while significantly increasing its biological resistance to proteolytic degradation.¹³⁹ More recently, the same group also reported the introduction of mutations in the cyclic analog of gomesin to reduce the cytotoxicity to eukaryotic cells while keeping the biological activities of gomesin.^{138,141}

Thanatin

Thanatin is a 21-residue pathogen-inducible antimicrobial peptide that, as gomesin, also adopts in solution a β -hairpin structure stabilized by a single-disulfide bond (Fig. 1 and Table 1).¹⁴² This antimicrobial peptide was originally isolated from the insect *Podisus maculiventris* and exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria as well as against

various species of fungi [see ref. 143 for a recent review on the antimicrobial properties of thanatin]. Thanatin presents low hemolytic activity and low toxicity against mammalian cells. MIC values range from \approx 0.5 μ M (*E. coli*) to \approx 30 μ M (*P. aeruginosa*). Thanatin is less active against Gram-positive bacteria, with MIC values ranging from \approx 2 μ M (*M. luteus*) to no activity (*S. aureus*).¹⁴² A comparison study across different disulfide-containing β -hairpin antimicrobial peptides indicates that thanatin had the lowest hemolytic and cytotoxic activity hence highlighting its potential for therapeutic applications.¹⁴³ Accordingly, the antimicrobial activity of thanatin and its analogs have been extensively studied *in vivo* with very promising results. For example, S-thanatin (thanatin with the T15S mutation) was shown to improve the survival rate in a septicemic mice model using the MDR clinical isolate of *K. pneumoniae* (CI120204205, resistant to carbapenems) from 0%, for the untreated mice group, to 100% for the mice group treated with 15 mg kg⁻¹ of the peptide.¹⁴⁴ A C-terminal amidated analog of thanatin (thanatin A) also increased the survival rate in an extended-spectrum β -lactamase-producing *E. coli* (ESBL-EC)-infected mice model from 0%, for the control group, to 92% for the mice treated with 10 mg kg⁻¹ of A-thanatin.¹⁴⁵

A recent report indicated that the binding of thanatin with periplasmic proteins involved in LPS transport to the outer membrane is the principal antimicrobial mode of action against Gram-negative bacteria.¹⁴⁶

The broad-spectrum antimicrobial activity of thanatin, in conjunction with its high *in vivo* stability and low cytotoxicity, are quite promising, although further research may be required before thanatin-based peptides can be developed into effective treatments against bacterial infection caused by MDR pathogenic bacteria. These studies should be focused on the development of more potent thanatin-based antimicrobial peptides. For example, more SAR studies on thanatin are still required to understand better how the sequence and structural modifications in the peptide composition can be translated into more active analogs.¹⁴³ In addition, more detailed studies are required on the mode of action of this peptide. The antibacterial activity of thanatin against Gram-positive bacteria and fungi remains largely unexplained as these microorganisms do not contain LPS or LPS-translocating protein complexes.

Concluding remarks

The spreading of antimicrobial-resistant genes in new bacterial strains is a matter of course and inevitable but this has been accelerated by the consequence of antibiotics abuse.¹⁴⁷ The search for new treatments should be urged to efficiently treat infections mediated by established and new MDR pathogenic bacterial strains.

Antimicrobial peptides are a highly diverse group of compounds that are being investigated as potentially attractive alternatives to classic antibiotics.¹⁴⁸ Among them, Cys-rich cyclic peptides have gained popularity holding many advantageous characteristics as therapeutic compounds in contrast to classical small molecule-based antibiotics. Among the different

examples reviewed in this manuscript, cyclotide-based antimicrobials are emerging as one of the most attractive alternatives for the design of novel antimicrobial peptides with broad-spectrum and effective in MDR pathogenic bacteria.

Cyclotides present extraordinary stability to thermal/chemical denaturation as well as to proteolytic degradation.¹⁴⁹ This high stability to proteolytic degradation and potential low cytotoxicity allows them to be used for the treatment of systemic infections.⁷⁷ In fact, proteolysis stability has been one of the main limitations associated with the development of antimicrobial peptides, which has limited their use mostly to topical applications.¹⁵⁰ Cyclotides can in some cases cross mammalian cellular membranes,^{103,151} which should also allow them to target intracellular bacteria. Intracellular bacteria remain one of the most challenging targets when designing novel antimicrobial peptide-based therapeutics.¹⁵⁰ Intracellular bacteria are also known to interfere with the host immune system to exacerbate the bacterial infection process.¹⁵⁰ Cyclotides and the circularized version of the antimicrobial peptide gomesin have been shown to cross mammalian cellular membranes^{103,141,151} and they have been shown to have potent antimicrobial activities in animal models of bacterial infection,⁷⁷ which makes them ideal candidates for further development into effective therapeutic agents able to target intracellular pathogens.

The small size of these peptides allows their chemical synthesis by using standard solid-phase peptide synthesis methods facilitating the use of structure–activity relationship (SAR) studies to improve their biological properties. This allows the introduction of chemical modifications such as PEGylation and/or non-natural amino acids to improve their pharmacological profiles, e.g., half-life extension and proteolytic stability.^{105,152}

In the case of the cyclotide scaffold, its high plasticity, tolerance to sequence variation, and the presence of up to five hypervariable loops make it an ideal substrate for molecular grafting and molecular evolution techniques to target a specific set of bacteria or bacterial targets.^{98,153} A recent study showcased the use of the cyclotide scaffold in the design of *de-novo* cyclotides with potent broad-spectrum antimicrobial activity.⁷⁷ The most active cyclotide (MCo-PG2) displayed better activity than colistin in a peritonitis infection model in mice.⁷⁷ Colistin is presently considered the last line of defense against human infections caused by multidrug-resistant Gram-negative organisms such as carbapenemase-producer *E. coli*, *A. baumannii*, and *P. aeruginosa*.¹⁵⁴ Cyclotide MCo-PG2 was also highly active against a panel ($N = 20$) of different MDR clinical isolates of *S. aureus* and *P. aeruginosa* indicating its high translational potential as an antimicrobial therapeutic lead.⁷⁷

Another exciting feature of cyclotides is the potential to be orally active. In fact, several bioactive cyclotides have already been reported as orally active,^{100,155} although more detailed pharmacological studies in this regard may be required in the future.

It is anticipated that some of the challenges still affect antimicrobial peptides before they can move into the clinic. These affect mostly immunogenicity and oral bioavailability, which should be soon addressed as novel and more potent antimicrobial peptides are reported.

Conflicts of interest

The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Acknowledgements

This work was supported by National Institutes of Health Research Grants R35-GM132072 (JAC). AM is partially supported by a postdoctoral fellowship “Ayudas Margarita Salas para la formación de jóvenes doctores” by University of León, Spain.

References

- 1 J. M. Pogue, K. S. Kaye, D. A. Cohen and D. Marchaim, *Clin. Microbiol. Infect.*, 2015, **21**, 302–312.
- 2 C. J. L. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. R. Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. K. Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castaneda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiu, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregebu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kisson, E. Kobeissi, T. Kostyanev, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. Victoria-Botham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimaikul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek, M. Naghavi and A. R. Collabora, *Lancet*, 2022, **399**, 629–655.
- 3 I. E. Kepiro, I. Marzuoli, K. Hammond, X. Ba, H. Lewis, M. Shaw, S. B. Gunnoo, E. De Santis, U. Lapinska, S. Pagliara, M. A. Holmes, C. D. Lorenz, B. W. Hoogenboom, F. Fraternali and M. G. Ryadnov, *ACS Nano*, 2020, **14**, 1609–1622.

- 4 G. Wang, B. Mishra, K. Lau, T. Lushnikova, R. Golla and X. Wang, *Pharmaceuticals*, 2015, **8**, 123–150.
- 5 R. Sher Khan, A. Iqbal, R. Malak, K. Shehryar, S. Attia, T. Ahmed, M. Ali Khan, M. Arif and M. Mii, *3 Biotech*, 2019, **9**, 192.
- 6 P. M. Silva, S. Goncalves and N. C. Santos, *Front. Microbiol.*, 2014, **5**, 97.
- 7 T. Tecle, S. Tripathi and K. L. Hartshorn, *Innate Immun.*, 2010, **16**, 151–159.
- 8 K. A. Brogden, M. Ackermann, P. B. McCray and B. F. Tack, *Int. J. Antimicrob. Agents*, 2003, **22**, 465–478.
- 9 D. P. McGregor, *Curr. Opin. Pharmacol.*, 2008, **8**, 616–619.
- 10 S. Srivastava, K. Dashora, K. L. Ameta, N. P. Singh, H. A. El-Enshasy, M. C. Pagano, A. E. Hesham, G. D. Sharma, M. Sharma and A. Bhargava, *Phytother. Res.*, 2021, **35**, 256–277.
- 11 A. Falanga, E. Nigro, M. G. De Biasi, A. Daniele, G. Morelli, S. Galdiero and O. Scudiero, *Molecules*, 2017, **22**, 1217.
- 12 C. K. Wang and D. J. Craik, *Nat. Chem. Biol.*, 2018, **14**, 417–427.
- 13 A. Gould and J. A. Camarero, *ChemBioChem*, 2017, **18**, 1350–1363.
- 14 M. E. Selsted and A. J. Ouellette, *Nat. Immunol.*, 2005, **6**, 551–557.
- 15 X. Gao, J. Ding, C. Liao, J. Xu, X. Liu and W. Lu, *Adv. Drug Delivery Rev.*, 2021, **179**, 114008.
- 16 M. E. Selsted, *Curr. Protein Pept. Sci.*, 2004, **5**, 365–371.
- 17 A. C. Conibear and D. J. Craik, *Angew. Chem., Int. Ed.*, 2014, **53**, 10612–10623.
- 18 J. P. Tam, S. Wang, K. H. Wong and W. L. Tan, *Pharmaceuticals*, 2015, **8**, 711–757.
- 19 J. Koehbach and D. J. Craik, *Trends Pharmacol. Sci.*, 2019, **40**, 517–528.
- 20 R. I. Lehrer and W. Lu, *Immunol. Rev.*, 2012, **245**, 84–112.
- 21 B. L. Kagan, M. E. Selsted, T. Ganz and R. I. Lehrer, *Proc. Natl. Acad. Sci. U. S. A.*, 1990, **87**, 210–214.
- 22 R. Lehrer, A. Barton, K. A. Daher, S. S. L. Harwig, T. Ganz and M. E. Selsted, *J. Clin. Invest.*, 1989, **84**, 553–561.
- 23 E. de Leeuw, C. Li, P. Zeng, C. Li, M. Diepeveen-de Buin, W. Y. Lu, E. Breukink and W. Lu, *FEBS Lett.*, 2010, **584**, 1543–1548.
- 24 F. Niyonsaba, H. Ushio, N. Nakano, W. Ng, K. Sayama, K. Hashimoto, I. Nagaoka, K. Okumura and H. Ogawa, *J. Invest. Dermatol.*, 2007, **127**, 594–604.
- 25 L. Steinstraesser, T. Koehler, F. Jacobsen, A. Daigeler, O. Goertz, S. Langer, M. Kesting, H. Steinau, E. Eriksson and T. Hirsch, *Mol. Med.*, 2008, **14**, 528–537.
- 26 D. Yang, Q. Chen, O. Chertov and J. J. Oppenheim, *J. Leukocyte Biol.*, 2000, **68**, 9–14.
- 27 M. C. Territo, T. Ganz, M. E. Selsted and R. Lehrer, *J. Clin. Invest.*, 1989, **84**, 2017–2020.
- 28 D. Yang, Z. H. Liu, P. Tewary, Q. Chen, G. de la Rosa and J. J. Oppenheim, *Curr. Pharm. Des.*, 2007, **13**, 3131–3139.
- 29 L. M. Rehaume and R. E. Hancock, *Crit. Rev. Immunol.*, 2008, **28**, 185–200.
- 30 M. G. Scott, A. C. Vreugdenhil, W. A. Buurman, R. E. Hancock and M. R. Gold, *J. Immunol.*, 2000, **164**, 549–553.
- 31 D. Motzkus, S. Schulz-Maronde, A. Heitland, A. Schulz, W. G. Forssmann, M. Jubner and E. Maronde, *FASEB J.*, 2006, **20**, 1701–1702.
- 32 N. Droin, J. B. Hendra, P. Ducoroy and E. Solary, *J. Proteomics*, 2009, **72**, 918–927.
- 33 E. Kudryashova, R. Quintyn, S. Seveau, W. Lu, V. H. Wysocki and D. S. Kudryashov, *Immunity*, 2014, **41**, 709–721.
- 34 R. I. Lehrer, G. Jung, P. Ruchala, W. Wang, E. D. Micewicz, A. J. Waring, E. J. Gillespie, K. A. Bradley, A. J. Ratner, R. F. Rest and W. Lu, *Infect. Immun.*, 2009, **77**, 4028–4040.
- 35 G. A. D. Blyth, L. Connors, C. Fodor and E. R. Cobo, *Front. Immunol.*, 2020, **11**, 965.
- 36 R. Bals, M. J. Goldman and J. M. Wilson, *Infect. Immun.*, 1998, **66**, 1225–1232.
- 37 Y. Q. Tang, J. Yuan, G. Osapay, K. Osapay, D. Tran, C. J. Miller, A. J. Ouellette and M. E. Selsted, *Science*, 1999, **286**, 498–502.
- 38 Q. Yu, R. I. Lehrer and J. P. Tam, *J. Biol. Chem.*, 2000, **275**, 3943–3949.
- 39 A. E. Garcia, K. P. Tai, S. S. Puttamadappa, A. Shekhtman, A. J. Ouellette and J. A. Camarero, *Biochemistry*, 2011, **50**, 10508–10519.
- 40 A. Maemoto, X. Qu, K. J. Rosengren, H. Tanabe, A. Henschen-Edman, D. J. Craik and A. J. Ouellette, *J. Biol. Chem.*, 2004, **279**, 44188–44196.
- 41 M. E. Pachon-Ibanez, Y. Smani, J. Pachon and J. Sanchez-Cespedes, *FEMS Microbiol. Rev.*, 2017, **41**, 323–342.
- 42 I. Ben-Efraim and Y. Shai, *Biophys. J.*, 1997, **72**, 85–96.
- 43 A. Mor and P. Nicolas, *J. Biol. Chem.*, 1994, **269**, 1934–1939.
- 44 Z. Oren and Y. Shai, *Biopolymers*, 1998, **47**, 451–463.
- 45 R. M. Dawson and C. Q. Liu, *Crit. Rev. Microbiol.*, 2008, **34**, 89–107.
- 46 C. J. Pridmore, A. Rodger and J. M. Sanderson, *Biochim. Biophys. Acta*, 2016, **1858**, 892–903.
- 47 B. Ericksen, Z. Wu, W. Lu and R. I. Lehrer, *Antimicrob. Agents Chemother.*, 2005, **49**, 269–275.
- 48 B. O. Schroeder, D. Ehmann, J. C. Precht, P. A. Castillo, R. Kuchler, J. Berger, M. Schaller, E. F. Stange and J. Wehkamp, *Mucosal Immunol.*, 2015, **8**, 661–671.
- 49 B. Mathew and R. Nagaraj, *Peptides*, 2015, **71**, 128–140.
- 50 B. O. Schroeder, Z. Wu, S. Nuding, S. Groscurth, M. Marciniowski, J. Beisner, J. Buchner, M. Schaller, E. F. Stange and J. Wehkamp, *Nature*, 2011, **469**, 419–423.
- 51 K. R. Parducho, B. Beadell, T. K. Ybarra, M. Bush, E. Escalera, A. T. Trejos, A. Chieng, M. Mendez, C. Anderson, H. Park, Y. Wang, W. Lu and E. Porter, *Front. Immunol.*, 2020, **11**, 805.
- 52 V. Sass, T. Schneider, M. Wilmes, C. Korner, A. Tossi, N. Novikova, O. Shamova and H. G. Sahl, *Infect. Immun.*, 2010, **78**, 2793–2800.
- 53 A. C. Conibear, C. K. Wang, T. Bi, K. J. Rosengren, J. A. Camarero and D. J. Craik, *J. Phys. Chem. B*, 2014, **118**, 14257–14266.
- 54 A. C. Conibear, K. J. Rosengren, N. L. Daly, S. T. Henriques and D. J. Craik, *J. Biol. Chem.*, 2013, **288**, 10830–10840.
- 55 W. Wang, C. Mulakala, S. C. Ward, G. Jung, H. Luong, D. Pham, A. J. Waring, Y. Kaznessis, W. Lu, K. A. Bradley and R. I. Lehrer, *J. Biol. Chem.*, 2006, **281**, 32755–32764.

- 56 Y. Li, A. Gould, T. Aboye, T. Bi, L. Breindel, A. Shekhtman and J. A. Camarero, *J. Med. Chem.*, 2017, **60**, 1916–1927.
- 57 T. Bi, Y. Li, A. Shekhtman and J. A. Camarero, *Bioorg. Med. Chem.*, 2018, **26**, 1212–1219.
- 58 A. Gould, Y. Li, S. Majumder, A. E. Garcia, P. Carlsson, A. Shekhtman and J. A. Camarero, *Mol. BioSyst.*, 2012, **8**, 1359–1365.
- 59 T. L. Aboye, Y. Li, S. Majumder, J. Hao, A. Shekhtman and J. A. Camarero, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 2823–2826.
- 60 R. A. Houghten, *Proc. Natl. Acad. Sci. U. S. A.*, 1985, **82**, 5131–5135.
- 61 T. J. Bensman, J. G. Jayne, M. Sun, E. Kimura, J. Meinert, J. C. Wang, J. B. Schaal, D. Tran, A. P. Rao, O. Akbari, M. E. Selsted and P. M. Beringer, *Antimicrob. Agents Chemother.*, 2017, **61**, e00154-17.
- 62 A. Seidel, Y. Ye, L. R. de Armas, M. Soto, W. Yarosh, R. A. Marcisin, D. Tran, M. E. Selsted and D. Camerini, *PLoS One*, 2010, **5**, e9737.
- 63 J. B. Schaal, D. Tran, P. Tran, G. Osapay, K. Trinh, K. D. Roberts, K. M. Brasky, P. Tongaonkar, A. J. Ouellette and M. E. Selsted, *PLoS One*, 2012, **7**, e51337.
- 64 E. M. Kosciuczuk, P. Lisowski, J. Jarczak, N. Strzalkowska, A. Jozwik, J. Horbanczuk, J. Krzyzewski, L. Zwierzchowski and E. Bagnicka, *Mol. Biol. Rep.*, 2012, **39**, 10957–10970.
- 65 V. N. Kokryakov, S. S. L. Harwig, E. A. Panyutich, A. A. Shevchenko, G. M. Aleshina, O. V. Shamova, H. A. Korneva and R. I. Lehrer, *FEBS Lett.*, 1993, **327**, 231–236.
- 66 T. Nakamura, H. Furunaka, T. Miyata, F. Tokunaga, T. Muta, S. Iwanaga, M. Niwa, T. Takao and Y. Shimonishi, *J. Biol. Chem.*, 1988, **263**, 16709–16713.
- 67 R. L. Fahrner, T. Dieckmann, S. S. Harwig, R. I. Lehrer, D. Eisenberg and J. Feigon, *Chem. Biol.*, 1996, **3**, 543–550.
- 68 L. Bellm, R. I. Lehrer and T. Ganz, *Expert Opin. Invest. Drugs*, 2000, **9**, 1731–1742.
- 69 B. Yasin, S. S. Harwig, R. I. Lehrer and E. A. Wagar, *Infect. Immun.*, 1996, **64**, 709–713.
- 70 H. Tamamura, A. Otaka, W. Takada, Y. Terakawa, H. Yoshizawa, M. Masuda, T. Ibuka, T. Murakami, H. Nakashima and M. Waki, *et al.*, *Chem. Pharm. Bull.*, 1995, **43**, 12–18.
- 71 B. Yasin, W. Wang, M. Pang, N. Cheshenko, T. Hong, A. J. Waring, B. C. Herold, E. A. Wagar and R. I. Lehrer, *J. Virol.*, 2004, **78**, 5147–5156.
- 72 J. P. Tam, C. Wu and J. L. Yang, *Eur. J. Biochem.*, 2000, **267**, 3289–3300.
- 73 E. Kudryashova, S. M. Seveau and D. S. Kudryashov, *Biol. Chem.*, 2017, **398**, 1069–1085.
- 74 N. Soundrarajan, S. Park, Q. L. V. Chanh, H. S. Cho, G. Raghunathan, B. Ahn, H. Song, J. H. Kim and C. Park, *Sci. Rep.*, 2019, **9**, 11569.
- 75 M. B. Marggraf, P. V. Panteleev, A. A. Emelianova, M. I. Sorokin, I. A. Bolosov, A. A. Buzdin, D. V. Kuzmin and T. V. Ovchinnikova, *Mar. Drugs*, 2018, **16**, 466.
- 76 J. Chen, T. J. Falla, H. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree, D. J. Loury, P. A. Radcliff, C. Cheng Chang, L. Gu and J. C. Fiddes, *Biopolymers*, 2000, **55**, 88–98.
- 77 R. Ganesan, M. A. Dughbaj, L. Ramirez, S. Beringer, T. L. Aboye, A. Shekhtman, P. M. Beringer and J. A. Camarero, *Chemistry*, 2021, **27**, 12702–12708.
- 78 D. A. Mosca, M. A. Hurst, W. So, B. S. Viajar, C. A. Fujii and T. J. Falla, *Antimicrob. Agents Chemother.*, 2000, **44**, 1803–1808.
- 79 O. Simonetti, O. Cirioni, R. Ghiselli, F. Orlando, C. Silvestri, S. Mazzocato, W. Kamysz, E. Kamysz, M. Provinciali, A. Giacometti, M. Guerrieri and A. Offidani, *Peptides*, 2014, **55**, 17–22.
- 80 B. Chaveli-Lopez and J. V. Bagan-Sebastian, *J. Clin. Exp. Dent.*, 2016, **8**, e201–209.
- 81 I. Martin-Loeches, G. E. Dale and A. Torres, *Expert Rev. Anti-Infect. Ther.*, 2018, **16**, 259–268.
- 82 N. Srinivas, P. Jetter, B. J. Ueberbacher, M. Werneburg, K. Zerbe, J. Steinmann, B. Van der Meijden, F. Bernardini, A. Lederer, R. L. Dias, P. E. Misson, H. Henze, J. Zumbunn, F. O. Gombert, D. Obrecht, P. Hunziker, S. Schauer, U. Ziegler, A. Kach, L. Eberl, K. Riedel, S. J. DeMarco and J. A. Robinson, *Science*, 2010, **327**, 1010–1013.
- 83 A. Luther, K. Moehle, E. Chevalier, G. Dale and D. Obrecht, *Curr. Opin. Chem. Biol.*, 2017, **38**, 45–51.
- 84 H. S. Sader, G. E. Dale, P. R. Rhomberg and R. K. Flamm, *Antimicrob. Agents Chemother.*, 2018, **62**, e00311-18.
- 85 H. S. Sader, R. K. Flamm, G. E. Dale, P. R. Rhomberg and M. Castanheira, *J. Antimicrob. Chemother.*, 2018, **73**, 2400–2404.
- 86 D. Chaudhuri, R. Ganesan, A. Vogelaar, M. A. Dughbaj, P. M. Beringer and J. A. Camarero, *J. Org. Chem.*, 2021, **86**, 15242–15246.
- 87 A. Wach, K. Dembowski and G. E. Dale, *Antimicrob. Agents Chemother.*, 2018, **62**, e02355-17.
- 88 J. Turner, Y. Cho, N. N. Dinh, A. J. Waring and R. I. Lehrer, *Antimicrob. Agents Chemother.*, 1998, **42**, 2206–2214.
- 89 M. Shahmiri, M. Enciso, C. G. Adda, B. J. Smith, M. A. Perugini and A. Mechler, *Sci. Rep.*, 2016, **6**, 38184.
- 90 M. Mahlapuu, A. Sidorowicz, J. Mikosinski, M. Krzyzanowski, J. Orleanski, K. Twardowska-Sauchka, A. Nykaza, M. Dyaczynski, B. Belz-Lagoda, G. Dziwiszek, M. Kujawiak, M. Karczewski, F. Sjoberg, T. Grzela, A. Wegrzynowski, F. Thunarf, J. Bjork, J. Ekblom, A. Jawien and J. Apelqvist, *Wound Repair Regen.*, 2021, **29**, 938–950.
- 91 J. K. White, T. Muhammad, E. Alsheim, S. Mohanty, A. Blasi-Romero, S. Gunasekera, A. A. Stromstedt, N. Ferraz, U. Goransson and A. Brauner, *Cell. Mol. Life Sci.*, 2022, **79**, 411.
- 92 X. Li, Y. Li, H. Han, D. W. Miller and G. Wang, *J. Am. Chem. Soc.*, 2006, **128**, 5776–5785.
- 93 G. Wang, *J. Biol. Chem.*, 2008, **283**, 32637–32643.
- 94 S. X. Ren, J. Shen, A. S. Cheng, L. Lu, R. L. Chan, Z. J. Li, X. J. Wang, C. C. Wong, L. Zhang, S. S. Ng, F. L. Chan, F. K. Chan, J. Yu, J. J. Sung, W. K. Wu and C. H. Cho, *PLoS One*, 2013, **8**, e63641.
- 95 S. Gunasekera, T. Muhammad, A. A. Stromstedt, K. J. Rosengren and U. Goransson, *ChemBioChem*, 2018, **19**, 931–939.
- 96 S. Gunasekera, T. Muhammad, A. A. Stromstedt, K. J. Rosengren and U. Goransson, *Front. Microbiol.*, 2020, **11**, 168.

- 97 J. Weidmann and D. J. Craik, *J. Exp. Bot.*, 2016, **67**, 4801–4812.
- 98 J. A. Camarero and M. J. Campbell, *Biomedicines*, 2019, **7**, 31.
- 99 K. J. Rosengren, N. L. Daly, M. R. Plan, C. Waine and D. J. Craik, *J. Biol. Chem.*, 2003, **278**, 8606–8616.
- 100 C. T. Wong, D. K. Rowlands, C. H. Wong, T. W. Lo, G. K. Nguyen, H. Y. Li and J. P. Tam, *Angew. Chem., Int. Ed.*, 2012, **51**, 5620–5624.
- 101 K. Thell, R. Hellinger, G. Schabbauer and C. W. Gruber, *Drug Discovery Today*, 2014, **19**, 645–653.
- 102 L. Cascales, S. T. Henriques, M. C. Kerr, Y. H. Huang, M. J. Sweet, N. L. Daly and D. J. Craik, *J. Biol. Chem.*, 2011, **286**, 36932–36943.
- 103 J. Contreras, A. Y. Elnagar, S. F. Hamm-Alvarez and J. A. Camarero, *J. Controlled Release*, 2011, **155**, 134–143.
- 104 W. G. Lesniak, T. Aboye, S. Chatterjee, J. A. Camarero and S. Nimmagadda, *Chemistry*, 2017, **23**, 14469–14475.
- 105 T. L. Aboye, H. Ha, S. Majumder, F. Christ, Z. Debyser, A. Shekhtman, N. Neamati and J. A. Camarero, *J. Med. Chem.*, 2012, **55**, 10729–10734.
- 106 T. Aboye, Y. Kuang, N. Neamati and J. A. Camarero, *Chem-BioChem*, 2015, **16**, 827–833.
- 107 Y. Ji, S. Majumder, M. Millard, R. Borra, T. Bi, A. Y. Elnagar, N. Neamati, A. Shekhtman and J. A. Camarero, *J. Am. Chem. Soc.*, 2013, **135**, 11623–11633.
- 108 D. J. Craik, R. J. Clark and N. L. Daly, *Expert Opin. Invest. Drugs*, 2007, **16**, 595–604.
- 109 B. Slazak, M. Kapusta, S. Malik, J. Bohdanowicz, E. Kuta, P. Malec and U. Goransson, *Planta*, 2016, **244**, 1029–1040.
- 110 J. A. Camarero, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 5089–5099.
- 111 C. Jennings, J. West, C. Waine, D. Craik and M. Anderson, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 10614–10619.
- 112 C. V. Jennings, K. J. Rosengren, N. L. Daly, M. Plan, J. Stevens, M. J. Scanlon, C. Waine, D. G. Norman, M. A. Anderson and D. J. Craik, *Biochemistry*, 2005, **44**, 851–860.
- 113 A. G. Poth, M. L. Colgrave, R. E. Lyons, N. L. Daly and D. J. Craik, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 10127–10132.
- 114 M. F. Pinto, I. C. Fensterseifer, L. Migliolo, D. A. Sousa, G. de Capdville, J. W. Arboleda-Valencia, M. L. Colgrave, D. J. Craik, B. S. Magalhaes, S. C. Dias and O. L. Franco, *J. Biol. Chem.*, 2012, **287**, 134–147.
- 115 D. J. Craik, *Toxins*, 2012, **4**, 139–156.
- 116 E. K. Gilding, M. A. Jackson, A. G. Poth, S. T. Henriques, P. J. Prentis, T. Mahatmanto and D. J. Craik, *New Phytol.*, 2016, **210**, 717–730.
- 117 M. L. Colgrave, A. C. Kotze, Y. H. Huang, J. O'Grady, S. M. Simonsen and D. J. Craik, *Biochemistry*, 2008, **47**, 5581–5589.
- 118 M. L. Colgrave, A. C. Kotze, D. C. Ireland, C. K. Wang and D. J. Craik, *ChemBioChem*, 2008, **9**, 1939–1945.
- 119 D. Malagon, B. Botterill, D. J. Gray, E. Lovas, M. Duke, C. Gray, S. R. Kopp, L. M. Knott, D. P. McManus, N. L. Daly, J. Mulvenna, D. J. Craik and M. K. Jones, *Biopolymers*, 2013, **100**, 461–470.
- 120 S. Troeira Henriques and D. J. Craik, *Biochemistry*, 2017, **56**, 669–682.
- 121 A. A. Stromstedt, S. Park, R. Burman and U. Goransson, *Biochim. Biophys. Acta, Biomembr.*, 2017, **1859**, 1986–2000.
- 122 J. P. Tam, Y. A. Lu, J. L. Yang and K. W. Chiu, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 8913–8918.
- 123 G. K. Nguyen, S. Zhang, W. Wang, C. T. Wong, N. T. Nguyen and J. P. Tam, *J. Biol. Chem.*, 2011, **286**, 44833–44844.
- 124 C. T. Wong, M. Taichi, H. Nishio, Y. Nishiuchi and J. P. Tam, *Biochemistry*, 2011, **50**, 7275–7283.
- 125 G. K. Nguyen, S. Zhang, N. T. Nguyen, P. Q. Nguyen, M. S. Chiu, A. Hardjojo and J. P. Tam, *J. Biol. Chem.*, 2011, **286**, 24275–24287.
- 126 M. Pranting, C. Loov, R. Burman, U. Goransson and D. I. Andersson, *J. Antimicrob. Chemother.*, 2010, **65**, 1964–1971.
- 127 I. C. Fensterseifer, O. N. Silva, U. Malik, A. S. Ravipati, N. R. Novaes, P. R. Miranda, E. A. Rodrigues, S. E. Moreno, D. J. Craik and O. L. Franco, *Peptides*, 2015, **63**, 38–42.
- 128 E. Grimsey, D. W. P. Collis, R. Mikut and K. Hilpert, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183195.
- 129 J. Koehbach, J. Gani, K. Hilpert and D. J. Craik, *Microorganisms*, 2021, **9**, 1249.
- 130 S. J. de Veer, A. M. White and D. J. Craik, *Angew. Chem., Int. Ed.*, 2021, **60**, 8050–8071.
- 131 M. L. Korsinczky, H. J. Schirra and D. J. Craik, *Curr. Protein Pept. Sci.*, 2004, **5**, 351–364.
- 132 M. L. Korsinczky, H. J. Schirra, K. J. Rosengren, J. West, B. A. Condie, L. Otvos, M. A. Anderson and D. J. Craik, *J. Mol. Biol.*, 2001, **311**, 579–591.
- 133 J. Austin, R. H. Kimura, Y. H. Woo and J. A. Camarero, *Amino Acids*, 2010, **38**, 1313–1322.
- 134 C. Wang, C. Shao, Y. Fang, J. Wang, N. Dong and A. Shan, *Acta Biomater.*, 2021, **124**, 254–269.
- 135 Y. L. Vishweshwaraiah, A. Acharya, V. Hegde and B. Prakash, *NPJ Sci. Food*, 2021, **5**, 26.
- 136 J. D. Tanner, E. Deplazes and R. L. Mancera, *Molecules*, 2018, **23**, 1733.
- 137 N. Mandard, P. Bulet, A. Caille, S. Daffre and F. Vovelle, *Eur. J. Biochem.*, 2002, **269**, 1190–1198.
- 138 S. Troeira Henriques, N. Lawrence, S. Chaouis, A. S. Ravipati, O. Cheneval, A. H. Benfield, A. G. Elliott, A. M. Kavanagh, M. A. Cooper, L. Y. Chan, Y. H. Huang and D. J. Craik, *ACS Chem. Biol.*, 2017, **12**, 2324–2334.
- 139 L. Y. Chan, V. M. Zhang, Y. H. Huang, N. C. Waters, P. S. Bansal, D. J. Craik and N. L. Daly, *ChemBioChem*, 2013, **14**, 617–624.
- 140 M. A. Fazio, V. X. Oliveira, Jr., P. Bulet, M. T. Miranda, S. Daffre and A. Miranda, *Biopolymers*, 2006, **84**, 205–218.
- 141 A. H. Benfield, S. Defaus, N. Lawrence, S. Chaouis, N. Condon, O. Cheneval, Y. H. Huang, L. Y. Chan, D. Andreu, D. J. Craik and S. T. Henriques, *Biochim. Biophys. Acta, Biomembr.*, 2021, **1863**, 183480.
- 142 P. Fehlbaum, P. Bulet, S. Chernysh, J. P. Briand, J. P. Roussel, L. Letellier, C. Hetru and J. A. Hoffmann, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 1221–1225.
- 143 R. Dash and S. Bhattacharjya, *Int. J. Mol. Sci.*, 2021, **22**, 1522.

- 144 G. Wu, P. Wu, X. Xue, X. Yan, S. Liu, C. Zhang, Z. Shen and T. Xi, *Peptides*, 2013, **45**, 73–77.
- 145 Z. Hou, J. Lu, C. Fang, Y. Zhou, H. Bai, X. Zhang, X. Xue, Y. Chen and X. Luo, *J. Infect. Dis.*, 2011, **203**, 273–282.
- 146 S. U. Vetterli, K. Zerbe, M. Muller, M. Urfer, M. Mondal, S. Y. Wang, K. Moehle, O. Zerbe, A. Vitale, G. Pessi, L. Eberl, B. Wollscheid and J. A. Robinson, *Sci. Adv.*, 2018, **4**, eaau2634.
- 147 F. Akram, M. Imtiaz and I. U. Haq, *Microb. Pathog.*, 2023, **174**, 105923.
- 148 A. Hollmann, M. Martinez, P. Maturana, L. C. Semorile and P. C. Maffia, *Front. Chem.*, 2018, **6**, 204.
- 149 D. Chaudhuri, T. Aboye and J. A. Camarero, *Biochem. J.*, 2019, **476**, 67–83.
- 150 A. Pfalzgraff, K. Brandenburg and G. Weindl, *Front. Pharmacol.*, 2018, **9**, 281.
- 151 Y. Ji, S. Majumder, M. Millard, R. Borra, T. Bi, A. Y. Elnagar, N. Neamati, A. Shekhtman and J. A. Camarero, *J. Am. Chem. Soc.*, 2013, **135**, 11623–11633.
- 152 T. Aboye, C. J. Meeks, S. Majumder, A. Shekhtman, K. Rodgers and J. A. Camarero, *Molecules*, 2016, **21**, 152.
- 153 B. Jacob, A. Vogelaar, E. Cadenas and J. A. Camarero, *Molecules*, 2022, **27**, 6430.
- 154 F. F. Andrade, D. Silva, A. Rodrigues and C. Pina-Vaz, *Microorganisms*, 2020, **8**, 1716.
- 155 K. Thell, R. Hellinger, E. Sahin, P. Michenthaler, M. Gold-Binder, T. Haider, M. Kuttke, Z. Liutkeviciute, U. Goransson, C. Grundemann, G. Schabbauer and C. W. Gruber, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 3960–3965.
- 156 M. Trabi, H. J. Schirra and D. J. Craik, *Biochemistry*, 2001, **40**, 4211–4221.
- 157 M. L. J. Korsinczky, H. J. Schirra, K. J. Rosengren, J. West, B. A. Condie, L. Otvos, M. A. Anderson and D. J. Craik, *J. Mol. Biol.*, 2001, **311**, 579–591.
- 158 K. J. Rosengren, N. L. Daly, L. M. Fornander, L. M. Jonsson, Y. Shirafuji, X. Qu, H. J. Vogel, A. J. Ouellette and D. J. Craik, *J. Biol. Chem.*, 2006, **281**, 28068–28078.
- 159 K. J. Rosengren, N. L. Daly, M. R. Plan, C. Waive and D. J. Craik, *J. Biol. Chem.*, 2003, **278**, 8606–8616.
- 160 D. M. Hoover, O. Chertov and J. Lubkowski, *J. Biol. Chem.*, 2001, **276**, 39021–39026.
- 161 D. M. Hoover, K. R. Rajashankar, R. Blumenthal, A. Puri, J. J. Oppenheim, O. Chertov and J. Lubkowski, *J. Biol. Chem.*, 2000, **275**, 32911–32918.
- 162 D. J. Schibli, H. N. Hunter, V. Aseyev, T. D. Starner, J. M. Wiencek, P. B. McCray, Jr., B. F. Tack and H. J. Vogel, *J. Biol. Chem.*, 2002, **277**, 8279–8289.
- 163 M. Trabi, H. J. Schirra and D. J. Craik, *Biochemistry*, 2001, 4211–4221.
- 164 E. Sancho-Vaello, D. Gil-Carton, P. Francois, E. J. Bonetti, M. Kreir, K. R. Pothula, U. Kleinekathofer and K. Zeth, *Sci. Rep.*, 2020, **10**, 17356.
- 165 Q. Y. Zhang, Z. B. Yan, Y. M. Meng, X. Y. Hong, G. Shao, J. J. Ma, X. R. Cheng, J. Liu, J. Kang and C. Y. Fu, *Mil. Med. Res.*, 2021, **8**, 48.